Trials / Terminated
TerminatedNCT03971825
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
A Phase 1, Randomized, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, randomized, single-center, 3-part, study to assess the safety, tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects and multiple doses of CC-92252 in adult subjects with psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-92252 | CC-92252 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2018-07-24
- Primary completion
- 2021-08-05
- Completion
- 2021-08-05
- First posted
- 2019-06-03
- Last updated
- 2021-08-30
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03971825. Inclusion in this directory is not an endorsement.